Epigen Pharmaceuticals Overview
- Founded
- 2013
- Status
- Out of Business
- Latest Deal Type
- Out of Business
Epigen Pharmaceuticals General Information
Description
Developer of cardiac reperfusion therapies designed to prevent ischemia-reperfusion injury. The company's therapies involves the use of histone deacetylase (HDAC) inhibitors for reducing myocardial infarct size following acute myocardial infarction and restoring normal blood flow, thereby assisting physicians with an effective pharmaceutical intervention for protecting the cardiomyocyte from reperfusion injury.
Contact Information
Website
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Therapeutic Devices
Primary Office
- 3160 Chestnut Street Suite- 200
- Philadelphia, PA 19104
- United States
+1 (215) 000-0000
Epigen Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 17-Sep-2020 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 01-Jan-2014 | Completed | Startup |